Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.69 |
| ▸ | CPB1 | P15086 | 15/20 | 0.58 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542661 | 0.95 | CPB2 (0.69) | CPB2CPB1CPA1 | |
| SCHEMBL2536326 | 0.95 | CPB2 (0.71) | CPB2CPB1CPA1 | |
| SCHEMBL2536330 | 0.91 | CPB2 (0.64) | CPB2CPB1CPA1 | |
| SCHEMBL2537227 | 0.91 | CPB1 (0.63) | CPB2CPB1CPA1 | |
| SCHEMBL2538193 | 0.91 | CPB2 (0.62) | CPB2CPB1CPA1 | |
| SCHEMBL2539197 | 0.90 | CPB2 (0.63) | CPB2CPB1CPA1 | |
| SCHEMBL2537417 | 0.89 | CPB2 (0.62) | CPB2CPB1CPA1 | |
| SCHEMBL2535980 | 0.89 | CPB2 (0.65) | CPB2CPB1CPA1 | |
| SCHEMBL2537248 | 0.88 | CPB2 (0.61) | CPB2CPB1CPA1 | |
| SCHEMBL2540887 | 0.88 | CPB2 (0.61) | CPB2CPB1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937673-B1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI SA (FR) | 2015-10-21 | — | — | EP | claimed |
| US-8044208-B2 | inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor); 3-(6-aminopyridin-3-yl)-2-{1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-imidazol-4-yl}propionic acid | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | claimed |
| US-20080262028-A1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | claimed |
| EP-1937673-B1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-8044208-B2 | inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor); 3-(6-aminopyridin-3-yl)-2-{1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-imidazol-4-yl}propionic acid | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20080262028-A1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1937673-A1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007045339-A1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262028-A1 | IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, TAF1 | CPB2 38/4885CPB1 51/4885CPA1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.